Phase 2 data show positive results for a therapy including 2 immune checkpoint inhibitors and chemotherapy.
All News
Advertisement
Top news of the day from across the health care landscape.
Advertisement
Top news of the day from across the health care landscape.
Amifampridine is an oral, nonspecific, voltage-dependent, potassium channel blocker that causes depolarization of a presynaptic membrane and slows or inhibits repolarization.
Early detection is vital to more patients with hepatitis C virus being eligible for increasingly efficient direct-acting antiviral treatment options.
Safety data came from both phase 3 studies as well as a phase 2 study of Dextenza, which together totaled 351 patients.
Advertisement
The research, a part of AmerisourceBergen’s first-ever Pharmacy Check-Up: Activity & Barriers to Care Analysis, examined various pharmacy settings.
A phase 2 study demonstrated promising response rates and overall survival in patients with acute myeloid leukemia who were treated with azacitidine plus nivolumab.
Abeparvovec (Zolgensma) is a one-time infusion that replaces the defective or missing SMN1 gene with a functional copy that can create the SMN protein and prevent the loss of motor neurons in patients with spinal muscular atrophy.
Top news of the day from across the health care landscape.
Advertisement
FDA finds rare but serious risks of stroke and blood vessel wall tears associated with the multiple sclerosis drug alemtuzumab (Lemtrada).
Top news of the day from across the health care landscape.
Can you solve the pharmaceutical mystery? Each week, a new case study is presented.
While scientists know more about the HIV infection than ever, and can prevent it from progressing into AIDS, there is still no known cure for the virus.
Top news of the day from across the health care landscape.
Technological advances have widened the potential solutions to improve adherence to high-cost specialty drugs.
Top news of the day from across the health care landscape.
It’s our job to spend as much time as it takes to help patients feel comfortable with the medications they are taking.
Top news of the week from Specialty Pharmacy Times.
Immunotherapy was first linked to cancer treatment in the late 19th century when surgeon William Coley discovered that the injection of bacteria into sarcoma sites led to tumor shrinkage.
The FDA advises health care providers to counsel patients receiving alemtuzumab on symptoms related to stroke and arterial dissection.
Epstein-Barr virus and Kaposi's sarcoma herpesvirus can activate and lead to the growth of cancerous cells.
Officials with the FDA have approved rituximab-abbs (Truxima, Celltrion) as a biosimilar to Rituxan (Genentech), making it the first biosimilar for the treatment of adult patients with non-Hodgkin’s lymphoma.
Top news of the day from across the health care landscape.
Top news of the day from across the health care landscape.
Amifampridine (Firdapse) is a first-in-class therapy for Lambert-Eaton myasthenic syndrome, a rare autoimmune disorder.
Amifampridine (Firdapse) is a first-in-class therapy for Lambert-Eaton myasthenic syndrome, a rare autoimmune disorder.
Your residency cover letter might be the most challenging part of the whole application process.
New platform would allow health care providers in developing nations to perform easy HIV testing and monitoring.
The drug’s application was designated for fast track and priority review, as well as orphan product status.
Advertisement
Advertisement
Trending on Pharmacy Times
1
TrumpRx Launches, Offering Cash-Paying Patients Discounted Drugs
2
Nipah Outbreak in India Poses Low Global Risk Despite Lack of Approved Treatments
3
Pharmacist Takeover: CAR T Therapy Signals a Shift in ALL Treatment
4
Q&A: Making Plant-Based Eating Practical in Pharmacy-Led Cardiometabolic Care
5